The rapid spread of azithromycin resistance in sexually transmitted infections caused by Mycoplasma genitalium is a growing concern. It is not yet clear to what degree macrolide resistance in M. genitalium results from the emergence of de novo mutations or the transmission of resistant strains. We analysed epidemiological data and developed a compartmental model to investigate the contribution of de novo macrolide resistance mutations to the spread of antimicrobial resistant M. genitalium. We fitted the model to data from France, Sweden and Denmark and estimated treatment rates and the time point of azithromycin introduction. In a meta-analysis of six studies, we estimated that de novo resistance develops in 12% (95% CI 7 -17%, I 2 44%) of M. genitalium infections treated with 1g azithromycin.
Introduction
Antimicrobial resistant Mycoplasma genitalium infections are increasingly common in many countries [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . M. genitalium is a sexually transmitted bacterium which, together with Chlamydia trachomatis, is an important cause of non-gonococcal urethritis (NGU) in men and of cervicitis in women [15, 16] . M. genitalium is detected using nucleic acid amplification tests (NAATs), which were first developed during the 1990s as research tools because the bacterium is slow-growing and extremely hard to culture. In most clinical settings, NAATs for M. genitalium diagnosis are not available. The clinical syndrome of NGU is treated empirically, with a single 1g dose of azithromycin recommended for first line treatment in many countries since the late 1990s [17] .
Macrolide resistance in M. genitalium results from a single nucleotide mutation in region V of the 23S rRNA gene, most commonly A2058G or A2059G. Jensen et al. identified these mutations in several Australian and Swedish men, with NGU caused by M. genitalium, who experienced clinical treatment failure with a single 1g dose of azithromycin [18] . The men carried a wild-type organism before treatment, but their post-treatment specimens contained mutations in the 23S rRNA gene that conferred macrolide resistance [18] . Since then, other investigators have also detected macrolide resistance mutations de novo (also known as acquired, induced or selected) in M. genitalium [7, 10, [19] [20] [21] [22] .
In many European countries, the proportion of resistant infections approaches 50% [4, 13, 14] . A study in Greenland that reported on specimens collected from 2008 to 2009 found that all specimens with M. genitalium harboured macrolide resistance mutations [9] . In Sweden, where azithromycin has only recently been recommended to treat laboratory diagnosed M. genitalium infections, the proportion of azithromycin resistant M. genitalium increased in one study from zero in 2006 to 21% in 2011 [10] . The increase in azithromycin resistance can explain a fall in microbiological cure of M. genitalium, from around 85% in studies published from 2000 to 2009 to around 67% from 2010 to 2015 [23, 24] . It is not yet clear to what degree the level of treatment failure in M. genitalium results from the emergence of de novo resistance mutations or the transmission of resistant strains. The objective of this study was to investigate the role of de novo emergence of resistance in the spread of azithromycin resistant M. genitalium.
Methods
We analysed epidemiological data about the proportion of M. genitalium infections with de novo mutations conferring macrolide resistance and about trends in the prevalence of M. genitalium resistance. We used the findings to inform the development of a mathematical model of the transmission of M. genitalium, which we fitted to resistance data. We used R 3.3.2 [25] for statistical analyses, transmission model simulations and parameter inference. We define de novo as a change from a drug-susceptible infection before treatment to a drug-resistant infection after treatment, either by selection of one or a few pre-existing resistant mutants in an otherwise drug-susceptible bacterial population or due to a novel resistance mutation evolving during drug exposure.
Epidemiological data
We searched Pubmed in March 2018 and updated the search on 4 th May 2018. We used the medical subject headings Mycoplasma genitalium AND drug resistance, bacterial and found 67 publications. Two authors independently screened the records for original research articles that provided data to address two questions.
Probability of emergence of de novo resistance: we included all studies that investigated patients with M. genitalium who received a single 1g dose of azithromycin and who had both pre-and post-treatment specimens tested for macrolide resistance mutations. From each included study we extracted the number of patients with macrolide resistance mutations detected only after treatment and the total number of patients tested. We combined the results from included studies in a meta-analysis. We used the Freeman-Tukey double arcsine transformation [26, 27] and used a random effects model to estimate the average proportion (with 95% confidence intervals, CI) of patients with initially macrolide susceptible M. genitalium who had macrolide resistance mutations detected after treatment (metaprop function from the R package meta 4.9).
Time trend in proportion of azithromycin resistant M. genitalium infections:
we searched for countries with multiple studies that reported on specimens tested for M. genitalium and for macrolide resistance mutations. We selected three countries that had data for more than three years from the same region of a country or from an entire country and used different strategies to test and treat M. genitalium. For each country, we recorded the region, M. genitalium testing strategy and treatment regimen, year in which azithromycin was introduced for the treatment of M. genitalium and, for each year, the total number of specimens with positive test results for M. genitalium and the number with macrolide resistance mutations. We contacted the study authors if this information was not available in the publication.
For each year, we calculated the proportion (with 95% CI) of azithromycin resistant M. genitalium.
Mathematical model
We developed a mathematical model that simulates the spread of drug resistance within a population ( Figure 1 ). The model consists of three compartments: susceptibles (S), people infected with a drug-susceptible strain of M. genitalium (IS), and people infected with a drug-resistant strain of M. genitalium (IR).
Assuming a homogenous population without demography, the transmission dynamics can be described by the following ordinary differential equations: 
where β is the transmission rate, which is assumed to be independent of the type of M. genitalium strain. Both types of infections can clear naturally at a rate γ. Patients receive treatment at a rate χ. The treatment rate is defined as all occasions of treatment with a single 1g dose of azithromycin in a person infected with M. genitalium, either with or without symptoms. µ denotes the probability of de novo resistance emergence during treatment. The de novo emergence of resistance also implies that the treatment failed. We used the point estimate of the probability of de novo resistance emergence from the meta-analysis. For simplicity, we assumed that there is no second-line treatment for resistant infections, which can thus only clear naturally.
The rate at which the drug-resistant strain replaces the drug-susceptible in a population can be expressed by the difference in the net growth rates (∆ ) between the two strains [27, 28] :
Model parameters
The natural clearance rate (γ) of M. genitalium infections has not been established and findings from empirical studies are inconsistent [30] . Based on values for other bacterial sexually transmitted infections, the natural clearance rate is likely to be at least in the order of months or years. We set the natural clearance rate γ to 0.8 y -1 , a published estimate based on epidemiological data and mathematical modelling [30] , and the infection rate ,β, to 0.816 person -1 y -1 . These values result in an equilibrium prevalence of M. genitalium infections of about 2% in the absence of any treatment, which is consistent with estimates of the prevalence of M. genitalium in the sexually active population in high-income countries [31, 32] . The values for the natural clearance rate and the prevalence of infection do not govern the relative growth rate of the drug-resistant proportion (Equation 6), so they do not influence the relative prevalence of resistant infections or estimates of the treatment rate in our model.
We did not find any published evidence of the effect of macrolide resistance on the fitness of M. genitalium strains, so we assumed that any fitness reduction is negligible and that a resistant strain has the same infectivity as a wild-type strain. 
Results

Model fitting and simulations
We fitted the transmission model to country-specific resistance data to obtain maximum likelihood estimates of the treatment rate χ and the time point T for the introduction of azithromycin. Given a model-predicted proportion of resistant strains = ( ) ( )+ ( ) in year i, the log-likelihood to find ki resistant samples in Ni tested individuals is:
Simulations start at time T with 98% uninfected people, 2% people with drug susceptible infections and no people with initial drug-resistant infections, which is the steady state prevalence in our model with our assumed clearance rate and infection rate in the absence of treatment. We used log-transformed parameters for the estimation and stipulated that the upper limit of T could not be beyond the time point where resistance was first observed. We derived simulation-based 95%
confidence intervals for the model curve from 10,000 bootstrap samples from the multivariate normal distribution of the two parameters. We used the ode function from the R package deSolve 1.20 to solve the ordinary differential equations, and the mle2 function from the R package bbmle 1.0.19 using the Nelder-Mead method for log-likelihood optimisation.
To investigate the influence of the level of de novo resistance emergence on the rise in the proportion of resistant infections, we simulated two alternative scenarios. In these scenarios, we kept the model-derived maximum likelihood estimates of χ and T but set the probability of de novo resistance emergence to lower values (μ = 1% and μ = 0.1%). As a sensitivity analysis we fitted the model to the country-specific data while assuming lower de novo resistance emergence probabilities of μ = 1% and μ = 0.1% and estimated both the resulting alternative χ and T values and the goodness of fit. The goodness of fit was measured with the aggregated negative log-likelihoods of the model fits relative to the country-specific data and the Akaike information criterion (AIC) [33] .
Results
Data
Probability of emergence of de novo resistance in M. genitalium
We included six studies that estimated the probability of de novo resistance emergence [7, 10, [19] [20] [21] [22] [7, 10, [19] [20] [21] [22] .
Time trend in proportion of azithromycin resistant M. genitalium infections
We included five studies that provided data about the proportion of azithromycinresistant M. genitalium infections over time and the management of M. genitalium infection in France [3, 8, 34] , Denmark [13] and Sweden [10] (supplementary table 2) .
Study authors provided additional information about the data from Denmark, for which data were pooled across consecutive years and Sweden, for which the exact numbers of patients per year as well as unpublished data for the years 2012 and 2013 were provided [10, 13] .
In France, we included three studies with data from 314 patients (310 from azithromycin was introduced for first line treatment of NGU in the 1990s [35] . For
Denmark, one study reported nationwide data from 1,008 patients with M.
genitalium detected from 2006 to 2010, with 27% to 42% of specimens containing macrolide resistance mutations [13] . In Denmark, 1g single dose azithromycin is routinely prescribed for treatment of NGU; erythromycin was the first line treatment before azithromycin became available. An extended azithromycin regimen is prescribed if a M. genitalium infection was diagnosed and NAAT for detection of M.
genitalium infections have been available since 2003 [13] . In Sweden, we analysed one study with data about macrolide resistance mutations from 408 samples obtained from 2006 to 2013 from patients at a single clinic in Falun [10] . Macrolide resistance mutations were first detected in a single specimen in 2008 and increased to 16% of 95 specimens in 2011. In Sweden, doxycycline is used as first line treatment for NGU [5, 36] . Azithromycin is used only when M. genitalium is identified as the cause, with testing introduced in the 2000s [10] .
Model
The In the sensitivity analysis, assuming de novo resistance emergence probabilities of 1% or 0.1%, the model estimated higher treatment rates, implausibly early time points of azithromycin introduction and worse goodness of fit (supplementary table   3 ). 
Discussion
In this study, we obtained a summary estimate of the probability of de novo emergence of resistance during therapy with 1g azithromycin of 12% (95% CI 7 - Alternative scenarios, where we assumed the estimated treatment rates and time points of azithromycin resistance and lower de novo resistance emergence probabilities, would result in considerably slower rise of M. genitalium resistance.
Strengths and weaknesses
A strength of this study is the use of empirical data sources and mathematical modelling. We obtained our estimate of the probability of de novo resistance from a meta-analysis of six studies, identified through a systematic literature search.
Parameters that were not available in the literature were estimated by fitting the model to observational data from France, Denmark, and Sweden, including however, observed in all three countries. We used a relatively simple transmission model, so we made several simplifying assumptions. First, we assumed that treatment rates in each country were constant over time and did not account for the possibility that azithromycin use might have risen over time. Second, we assumed that no second line treatments were used for resistant M. genitalium infections. If we implemented treatment of resistant infections, our estimates for the initial treatment rate for susceptible infections would have been somewhat higher. In practice, since most M. genitalium infections are asymptomatic and diagnostic testing is still uncommon, we do not think that this simplification affected our results much. Third, our model does not include detailed population structure because the rate at which the relative proportion of resistant bacterial strains spread in a population can often be explained by the treatment rate, rather than the sexual network structure [29] . More complex models with different sexes, partner change rates, age structure, and a better understanding of the average infectious duration of M. genitalium, would be necessary to obtain a better description of the absolute prevalence of infections and resistance, but this was not the objective of this study.
Interpretation and comparison with other studies
This study strongly suggests that, rather than resulting in 'occasional treatment failure' as originally believed [18] , the development of de novo resistant mutations in 12% (95% CI 7 -17%) of M. genitalium infections is the main driver of azithromycin resistance. The data from France and Sweden [3, 8, 10, 34] , where no macrolide resistant mutations were detected initially, show a substantial proportion of diagnosed M. genitalium infections with azithromycin resistance after just a few years of azithromycin use. Our model shows that a high de novo resistance acquisition rate contributes considerably to the spread of resistance, particularly during the early stages of its occurrence. The effect then decreases as the proportion of resistant infections increases. This pattern contrasts with alternative scenarios in which resistance emerges with a lower probability. Then, the effect on the growth rate would be substantially smaller and the growth dynamics of the drug resistant proportion are much closer to a logistic growth model. Assuming the same treatment rate and time point of introduction of azithromycin, this growth dynamic would require much more time to reach the levels of resistance that we observed in France, Denmark and Sweden. Our model-predicted estimates of the introduction of azithromycin for the treatment of NGU were consistent with published data describing its use in France [35] and Denmark in the 1990s, but later introduction in Sweden [10] . Our estimated treatment rate for France was lower than those for Denmark and Sweden but the 95% confidence intervals of all three estimates overlap. The estimated rates in Sweden and Denmark are very close to those estimated in another epidemiological model of M. genitalium infections in the United Kingdom [37] . We have not found other mathematical modelling studies that have investigated the role of de novo mutations in the spread of antimicrobial resistant M. genitalium.
The high probability of de novo emergence of macrolide resistance mutations during treatment of M. genitalium infections appears to differ from experiences with some other sexually transmitted bacterial infections. A 1g dose of azithromycin might often be insufficient to eradicate a M. genitalium infection in concert with host immune responses, allowing for either a resistance mutation to occur in the single 23S rRNA operon during treatment or the survival of a few pre-existing drugresistant bacteria and the subsequent selection of the mutants. The latter explanation is favoured by the strong association with de novo resistance and high organism load [20, 22, 38] , but both mechanisms may play a role. In the absence of any observable fitness cost, or of routine tests to detect macrolide resistance mutations, M. genitalium resistance has emerged and spread rapidly. In contrast, selection pressure exerted by treatment and clonal spread are the major drivers of the spread of antimicrobial resistant Neisseria gonorrhoeae, with de novo resistance considered to be negligible [29] . N. gonorrhoeae has four copies of the 23S rRNA gene and resistance increases with the number of mutated copies [39] . In addition, active measures, such as combination therapy with ceftriaxone, are used to limit the potential for the emergence of de novo macrolide resistance in N. gonorrhoeae.
Azithromycin resistance is also recognised in Treponema pallidum [40] , but azithromycin monotherapy is not recommended as treatment for syphilis.
Transmitted resistance is assumed to be responsible for most antimicrobial resistance, but a high rate of de novo resistance emergence has been observed during treatment with various antibiotics of other bacterial infections, such as
Pseudomonas aeruginosa and Enterobacteriaceae [41] [42] [43] . In general, de novo selection of drug-resistant mutants within a single patient occurs more often if the resistance is mediated by single-base mutations than if acquisition of efflux pumps or other complex mechanism are needed [44] . Thus, it is distinct from the selection of drug resistance as a result of treatment at the population level which is more often transmitted; a situation which is seen with most other bacterial and parasitic sexually transmitted infections.
Implications for research and practice
The high level of azithromycin resistance in M. genitalium, driven by de novo resistance, poses problems for clinical management and population level control strategies [45] . Screening and treatment of asymptomatic M. genitalium would simply result in the spread of more strains with de novo mutations, with absent evidence of a reduction in clinical morbidity [45] . The deployment for widespread testing of NAATs with multiplexed detection of M. genitalium, C. trachomatis and N.
gonorrhoeae [46] should be resisted. The focus should be on strategies to improve surveillance of de novo antimicrobial resistant M. genitalium infections and to improve the management of symptomatic infection, whilst minimising the emergence of resistance since resistance to second line treatment with moxifloxacin is already increasing [6] . Calls to abandon treatment of uncomplicated NGU with single dose azithromycin [24, [47] [48] [49] and to return to doxycycline [50] are increasing.
Despite concerns about limited efficacy of doxycycline, a large randomised controlled trial conducted in the US from 2007 to 2011 found that both clinical and microbiological cure rates for doxycycline and azithromycin were comparable [51] .
Evidence for the effectiveness of higher doses or extended regimens of azithromycin is mixed and the proportions of patients that develop macrolide resistance mutations with single dose and a five-day regimen were comparable in one study [22] . New antimicrobials or combination therapy that might have a lower propensity for the emergence of de novo resistance are being investigated [52] . Implementation of clinical guidelines could help to improve consistent management. The first European guidelines for the management of M. genitalium and updated guidelines for NGU [50, 53] , both published in 2016, recommend that a test to detect macrolide resistance mutations [54] should accompany diagnostic testing for M. genitalium.
Trials are needed to determine how proposed treatment algorithms, based on the results of resistance testing and follow-up tests of cure, affect the emergence of M. genitalium resistance. Since de novo resistance is the main driver of azithromycin resistance in M. genitalium, enhanced surveillance is needed and clinical management strategies for M. genitalium should seek to limit the unnecessary use of macrolides.
